Danish Trade Distributors Stock News

Novo Nordisk's key semaglutide patent has expired in India, opening the door for local drugmakers to launch generic versions. The change is expected to lead to lower cost options for obesity and diabetes treatment across the Indian market. Hospitals and providers in India are preparing new obesity treatment programs in anticipation of higher demand. The patent shift in India arrives at a time when Novo Nordisk, ticker CPSE:NOVO B, is under pressure in equity markets. The shares last closed...

Recent price performance and business mix GN Store Nord (CPSE:GN) has attracted attention after a 0.2% one day move and double digit gains over the past week, contrasting with weaker returns over the past year and past 3 months. For readers trying to put this swing into context, it helps to look at the current financial snapshot and how the business is split across its core segments and regions. GN Store Nord reports annual revenue of DKK 16,782 and net income of DKK 653, supported by three...

Lundbeck’s plan to share new Phase 1b data on Lu AF28996 and advances in multiple system atrophy research, including the partnered antibody amlenetug, puts Genmab (CPSE:GMAB) back on investors’ radar this week. See our latest analysis for Genmab. Genmab’s latest neurological partnership headlines arrive after a softer patch for the shares, with a 1 month share price return of 9.98% and a year to date share price return of 14.57%. The 1 year total shareholder return of 22.51% contrasts with...

Why Zealand Pharma stock is in focus after new obesity trial data Zealand Pharma (CPSE:ZEAL) has moved into the spotlight after announcing that its investigational obesity therapy petrelintide met the primary endpoint in a large Phase 2 trial, showing statistically significant weight loss versus placebo. See our latest analysis for Zealand Pharma. The positive petrelintide data arrives after a difficult period for Zealand Pharma shareholders. A 30 day share price return of 29.15% and a 90 day...

With no specific news event driving Ringkjøbing Landbobank (CPSE:RILBA) today, the stock’s recent performance and valuation metrics offer a starting point for assessing whether its current DKK 1,508 price looks appealing. See our latest analysis for Ringkjøbing Landbobank. The recent dip in Ringkjøbing Landbobank’s 1 month share price return of 7.94% contrasts with its 1 year total shareholder return of 23.33%, which may suggest cooling momentum after a strong multi year run supported by a...

Ørsted (CPSE:ORSTED) just reached a key project milestone as the Revolution Wind joint venture began feeding electricity into New England’s grid, backed by fixed-price, 20-year contracts with utilities in Rhode Island and Connecticut. See our latest analysis for Ørsted. The latest progress at Revolution Wind comes as Ørsted’s share price, now at DKK149.05, has a 90 day share price return of 9.6% and a year to date share price return of 16.45%. However, the 1 year total shareholder return is...

For investors wondering whether Bavarian Nordic at DKK181.55 is a bargain or already pricing in its prospects, this article walks through the key numbers that may matter. The share price has recorded a 0.2% decline over the past week and is down 5.4% over the last month, while still showing a 9.3% gain over the past year. Recent coverage around Bavarian Nordic has focused on its position within the wider pharmaceuticals and biotech space, giving investors more context on how its pipeline and...

Københavns Lufthavne (CPSE:KBHL) has wrapped up FY 2025 with Q4 revenue of DKK 1,368 million and basic EPS of DKK 32.95, while trailing twelve month figures sit at DKK 5.5 billion in revenue and EPS of DKK 158.00, reflecting earnings growth of 19.6% over the period. The company has seen quarterly revenue move from DKK 1,245 million and EPS of DKK 24.98 in Q4 2024 to DKK 1,368 million and EPS of DKK 32.95 in Q4 2025, with margins stepping up from 20% to 22%. This puts profitability at the...

Earlier this month, Zealand Pharma reported positive topline Phase 2 ZUPREME-1 results showing petrelintide achieved statistically significant, clinically meaningful weight loss with tolerability similar to placebo in people living with overweight and obesity. The data suggest petrelintide’s once-weekly amylin-based profile could offer a differentiated, potentially more tolerable alternative to existing peptide weight-loss therapies, reinforcing Zealand’s obesity franchise with Roche. We’ll...

Danske Bank has reduced its equity overweight in its asset management portfolios in response to escalating tensions in the Middle East. The bank's research team is highlighting potential oil price shocks linked to disruptions in key energy supply routes. These adjustments reflect a focus on managing geopolitical and commodity risk across client portfolios. For investors watching CPSE:DANSKE, the move comes with the shares at DKK316.6 and a 1 year return of 41.1%. Over 3 years the stock has...

Bank of England contract puts ISS (CPSE:ISS) in focus ISS (CPSE:ISS) has attracted fresh investor attention after announcing a new 4 year integrated facilities services contract, with a 1 year extension option, with the Bank of England across multiple UK sites. See our latest analysis for ISS. The Bank of England win comes as ISS shares trade at DKK217.0, with a 16.6% decline in the 1 month share price return contrasting with a 34.33% 1 year total shareholder return, suggesting longer term...

A.P. Møller - Mærsk has formed a new UK defence supply chain alliance with Amentum, GXO Logistics and Accenture. The partnership focuses on defence readiness and supply chain resilience for mission critical government operations. The move extends Maersk's integrated logistics offering into higher security, technology driven contracts in the defence sector. A.P. Møller - Mærsk (CPSE:MAERSK B) is adding a new leg to its business with this defence focused alliance, alongside its core global...

Earnings event puts Københavns Lufthavne (CPSE:KBHL) in focus Københavns Lufthavne (CPSE:KBHL) just released full year 2025 results, reporting higher sales, revenue, and net income than the prior year. This has put the airport operator’s profitability and recent share performance under closer investor scrutiny. See our latest analysis for Københavns Lufthavne. The earnings release comes after a mixed year in the market, with the share price at DKK6,440 and recent gains such as a 1 day share...

If you are wondering whether TORM's current share price lines up with its underlying worth, you are not alone and this article is built to help you frame that question clearly. The stock last closed at DKK 158.70, after a 14.0% decline over the past week, a 0.6% decline over the last month, but with returns of 26.8% year to date and 45.0% over the past year. These moves have put TORM on the radar for investors who track shipping and tanker companies, and they raise the question of what is...

Evaluating Bavarian Nordic after recent share performance Bavarian Nordic (CPSE:BAVA) has drawn attention after a mixed stretch for the shares, with a 1 day gain of about 2.2% but declines over the past week, month and past 3 months. For investors tracking longer horizons, the stock shows a positive 1 year total return and a modest gain over 3 years. This is set against a weaker 5 year outcome, which naturally raises questions about how the current valuation lines up with fundamentals. See...

Columbus (CPSE:COLUM) has wrapped up FY 2025 with fourth quarter revenue of DKK 385.5 million and basic EPS of DKK 0.05, setting a mixed tone after a year that included both profitable and loss‑making quarters. Over recent periods the company has seen quarterly revenue move from DKK 416.9 million and EPS of DKK 0.23 in Q4 2024, through swings such as Q1 2025 revenue of DKK 434.0 million with EPS of DKK 0.20 and Q2 2025 revenue of DKK 409.9 million with a loss per share of DKK 0.06, before...

If you are wondering whether Novo Nordisk's current share price really reflects its underlying worth, you are not alone. This article is here to walk you through that question step by step. After a strong long term story, the stock is now sitting at DKK 247.05 following a 0.3% decline over the last 7 days, a 19.4% decline over 30 days, a 25.2% decline year to date and a 52.1% decline over the past year, with a 22.2% return over 5 years and a 46.8% return over 3 years. Recent headlines around...

If you are wondering whether GN Store Nord's current share price reflects its true worth, you are not alone. This article is built to help you make sense of what the market is pricing in. GN Store Nord shares last closed at DKK 87.08, with returns of 6.2% decline over 7 days, 11.8% decline over 30 days, 20.8% decline year to date, 26.3% decline over 1 year, 39.0% decline over 3 years and 81.8% decline over 5 years. These moves may have shifted how investors think about both risk and...

Wondering if A.P. Møller - Mærsk is priced for its future or its past? This article walks you through what the current share price might be telling you about value. The stock closed at DKK 16,230, with returns of 6.6% over 30 days, 10.5% year to date and 46.1% over 1 year, so recent moves may have changed how you think about both upside and risk. Recent news has focused on Maersk's position in global container shipping and investor interest in how trade flows, freight demand and supply chain...

Scandinavian Tobacco Group (CPSE:STG) has drawn fresh attention after reporting full year 2025 results with lower sales and net income, issuing 2026 guidance, and proposing a reduced DKK 4.50 dividend per share. See our latest analysis for Scandinavian Tobacco Group. The latest earnings release and reduced dividend appear to have weighed on sentiment, with a 30 day share price return showing a decline of 32.61% and a year to date share price return showing a decline of 29.47%, while the 1...

If you are wondering whether Vestas Wind Systems is still priced attractively after a strong run, this article walks through how its current share price stacks up against different valuation checks. The stock trades at DKK159.70 after a 54.1% return over the past year, even though the 7 day, 30 day and year to date returns of 0.2% decline, 2.1% decline and 10.6% decline show that the ride has not been smooth. Recent coverage has focused on Vestas as a key player in global wind power build...

Investors may be wondering if Coloplast at around kr439.80 is starting to look interesting again, or if the current price still feels rich compared to its fundamentals. The share price has recorded a 4.7% decline over the last 7 days, a 10.6% decline over 30 days, an 18.0% decline year to date and a 37.1% decline over 1 year, while the 3 year and 5 year returns sit at declines of 41.9% and 45.6% respectively. These moves come as investors reassess the company against peers in the healthcare...

Novo Nordisk has received a formal warning letter from the US Food and Drug Administration regarding post marketing safety reporting. The FDA identified issues in how the company handled adverse event reports for certain products, including semaglutide. The warning highlights regulatory concerns around the company’s compliance with US drug safety reporting rules. For investors following CPSE:NOVO B, this regulatory setback comes at a time when the share price stands at DKK247.0. The stock...

Bavarian Nordic (CPSE:BAVA) has wrapped up FY 2025 with Q4 revenue of DKK 1.5b and a basic EPS loss of DKK 4.13, capping a year in which trailing twelve month revenue came in at DKK 6.2b and basic EPS at DKK 17.6. Over the past few quarters, the company has seen revenue move from DKK 1.3b in Q1 2025 to DKK 1.8b in Q3 2025 before landing at DKK 1.5b in Q4, while quarterly basic EPS ranged from DKK 2.7 in Q1 and DKK 13.7 in Q3 to a loss in Q4. With trailing net profit margin at 22% compared to...